Loading
Venetoclax plus obinutuzumab, one year of a pill plus an antibody, was the first fixed-duration, chemotherapy-free CLL regimen, with half of patients still in remission at six years.
This combination gives one year of venetoclax, a BCL-2 inhibitor, with the CD20 antibody obinutuzumab in chronic lymphocytic leukaemia; it was the first fixed-duration, chemotherapy-free regimen for the disease. Obinutuzumab debulks the leukaemia and reduces the risk of tumour lysis syndrome before venetoclax is ramped up, and adds antibody-dependent cellular cytotoxicity, while venetoclax clears measurable residual disease. The evidence is two positive phase 3 trials: CLL14 in unfit patients, where a large share remain in remission at long follow-up, and CLL13 (GAIA) in fit patients, where obinutuzumab outperformed rituximab as the venetoclax partner and adding ibrutinib deepened the effect further. The regimen is described in the CLL14 paper.
Shares CLL14, CLL13 / GAIA, CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients, Obinutuzumab.
Shares CLL14, CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients, BCL-2, CD20.
Shares CLL13 / GAIA, BCL-2, CD20, Venetoclax.
Shares CLL14, CLL13 / GAIA, Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
Shares Obinutuzumab, Chronic lymphocytic leukaemia, first treatment, BCL-2, CD20.
Shares Obinutuzumab, Chronic lymphocytic leukaemia, first treatment, BCL-2, Venetoclax.
Shares CLL13 / GAIA, Obinutuzumab, Chronic lymphocytic leukaemia, first treatment, BCL-2.
Shares Obinutuzumab, Chronic lymphocytic leukaemia, first treatment, Venetoclax, Chronic lymphocytic leukaemia.